Overview
Third Harmonic Bio is a clinical-stage biopharmaceutical company that is advancing the next wave of medicine for allergy and inflammation for the treatment of dermal, respiratory and gastrointestinal diseases.

Our lead program, THB-001, is a potent and highly selective, oral small molecule inhibitor of KIT, a master regulator of mast cell function and survival. Mast cells have long been known to be a central driver of allergic and inflammatory processes. By inhibiting KIT, THB-001 is expected to inactivate and deplete mast cells, providing the potential for broad symptomatic relief across a range of inflammatory diseases.

With “pipeline-in-a-product” potential, THB-001 is entering Phase 1b clinical trials for chronic inducible urticaria, a dermatologic disease driven by mast cell activation, resulting in red, itchy, painful wheals or hives that can severely impact a patient’s quality of life.

News
Julie Person Joins Third Harmonic Bio as Chief Administrative Officer
Third Harmonic Bio Appoints Edward R. Conner, M.D., as Chief Medical Officer 
Third Harmonic Bio Strengthens Management Team with Addition of Adrian S. Ray, Ph.D., as Chief Scientific Officer 
Third Harmonic Bio Appoints Robert Ho as Chief Financial Officer
Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation
Events
Event title to come…Lorem ipsum dolor sit amet, consectetuer adipiscing
Event title to come…Lorem ipsum dolor sit amet, consectetuer adipiscing
Event title to come…Lorem ipsum dolor sit amet, consectetuer adipiscing
Latest presentation
Advancing the Next Wave of Medicine for Allergy and Inflammation
Investor contact

Contact Third Harmonic Bio investor relations at
investors@thirdharmonicbio.com